Switch theme
Sign up to access all valuation multiples
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
2018
103
Last FY Revenue n/a
LTM EBITDA -$173M
$141M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Erasca has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$173M.
In the most recent fiscal year, Erasca achieved revenue of n/a and an EBITDA of -$153M.
Erasca expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Erasca valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$173M | XXX | -$153M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$170M | XXX | -$157M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$152M | XXX | -$162M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Erasca's stock price is $1.
Erasca has current market cap of $395M, and EV of $141M.
See Erasca trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $141M | $395M | XXX | XXX | XXX | XXX | $-0.60 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Erasca has market cap of $395M and EV of $141M.
Erasca's trades at n/a EV/Revenue multiple, and -0.9x EV/EBITDA.
Equity research analysts estimate Erasca's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Erasca has a P/E ratio of -2.6x.
See valuation multiples for Erasca and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $395M | XXX | $395M | XXX | XXX | XXX |
| EV (current) | $141M | XXX | $141M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -0.8x | XXX | -0.9x | XXX | XXX | XXX |
| EV/EBIT | -0.8x | XXX | -0.9x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -2.6x | XXX | -2.4x | XXX | XXX | XXX |
| EV/FCF | -1.6x | XXX | -1.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialErasca's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.5M for the same period.
Erasca's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Erasca's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Erasca and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 2% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Erasca acquired XXX companies to date.
Last acquisition by Erasca was XXXXXXXX, XXXXX XXXXX XXXXXX . Erasca acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Erasca founded? | Erasca was founded in 2018. |
| Where is Erasca headquartered? | Erasca is headquartered in United States of America. |
| How many employees does Erasca have? | As of today, Erasca has 103 employees. |
| Who is the CEO of Erasca? | Erasca's CEO is Dr. Jonathan E. Lim,M.D.. |
| Is Erasca publicy listed? | Yes, Erasca is a public company listed on NAS. |
| What is the stock symbol of Erasca? | Erasca trades under ERAS ticker. |
| When did Erasca go public? | Erasca went public in 2021. |
| Who are competitors of Erasca? | Similar companies to Erasca include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Erasca? | Erasca's current market cap is $395M |
| Is Erasca profitable? | Yes, Erasca is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Erasca? | Erasca's last 12 months EBITDA is -$173M. |
| What is the current EV/EBITDA multiple of Erasca? | Current EBITDA multiple of Erasca is -0.8x. |
| What is the current FCF of Erasca? | Erasca's last 12 months FCF is -$90.6M. |
| What is the current EV/FCF multiple of Erasca? | Current FCF multiple of Erasca is -1.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
